NCT02133742 - A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 16, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

July 3, 2019

Conditions

Renal Cell Carcinoma

Interventions

DRUG

Axitinib

Axitinib at starting dose of 5 mg and 3 mg BID.

DRUG

MK-3475

MK-3475 with two dose levels: 2 mg/kg every three weeks to find the maximum tolerated dose and continue treatment in a dose expansion phase.

Trial Locations (19)

10016

Attn. Alicia Sammarco, RPh, NYU Investigational Pharmacy, New York

NYU Langone Medical Center, New York

NYU Langone, New York

14263

Roswell Park Cancer Institute, Buffalo

19111

Fox Chase Cancer Center, Philadelphia

20007

Georgetown University Medical Center, Washington D.C.

33612

H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa

37232

Henry-Joyce Cancer Clinic, Nashville

Vanderbilt Oncology Pharmacy, Nashville

43210

Investigational Drug Services, Columbus

James Cancer Hospital, Columbus

The Ohio State University Brain and Spine Hospital, Columbus

43221

Martha Morehouse Medical Plaza, Columbus

48201

Karmanos Cancer Institute, Detroit

75246

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

02114

Massachusetts General Hospital, Boston

02115

Brigham & Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston